文章摘要

复方甘草酸苷治疗乙型肝炎肝硬化的疗效及对血清IL-17,IL-6,TGF-β和MMP-2水平的影响

作者: 1袁媛, 1陈洁, 1杨雪梅, 1邓兰
1 成都医学院第一附属医院感染科,成都 610500
通讯: 袁媛 Email: 14334202@qq.com
DOI: 10.3978/j.issn.2095-6959.2020.08.025
基金: 四川省医学会感染性肝病(深圳健安)专项科研课题(2017SZJA09)。

摘要

目的:研究复方甘草酸苷治疗乙型肝炎肝硬化患者的疗效及对血清IL-17,IL-6,TGF-β和MMP-2水平的影响。方法:选取成都医学院第一附属医院感染科2017年1月至2018年12月期间收治的90例乙型肝炎肝硬化患者分为观察组(n=45)和对照组(n=45)。观察组在对照组治疗的基础上加用复方甘草酸苷,检测生化指标谷丙转氨酶(alanine aminotransfem,ALT)、谷氨酰转肽酶(glutamyltransferase,GGT)、白蛋白(albumin,ALB)、总胆红素(total bilirubin,TBIL)、肝纤维化指标透明质酸(hyaluronic acid,HA)、层黏连蛋白(Laminin,LN)、IV型胶原(type IV collagen,IV-C)和III型前胶原(type III procollagen,PC-III)水平以及细胞因子IL-17,IL-6,TGF-β和MMP-2水平。结果:治疗后,两组ALT,GGT及TBIL水平均显著降低(均P<0.05),观察组ALT,GGT及TBIL均显著低于对照组(均P<0.05)。治疗后,两组患者LN,HA,IV-C及PC-III水平均显著降低(均P<0.05),观察组LN,HA,IV-C及PC-III均显著低于对照组(均P<0.05)。治疗后,两组血清IL-17,IL-6,TGF-β及MMP-2均显著降低(均P<0.05),观察组IL-17,IL-6,TGF-β及MMP-2均显著低于对照组(均P<0.05)。结论:复方甘草酸苷能够改善乙型肝炎肝硬化患者的肝功能,降低血清IL-17,IL-6,TGF-β及MMP-2的水平。
关键词: 复方甘草酸苷;乙型肝炎肝硬化;IL-17;IL-6;TGF-β;MMP-2

Efficacy of compound glycyrrhizin in the treatment of hepatitis B cirrhosis and its effect on serum levels of IL-17, IL-6, TGF-β and MMP-2

Authors: 1YUAN Yuan, 1CHEN Jie, 1YANG Xuemei, 1DENG Lan
1 Department of Infectious Disease, First Affiliated Hospital of Chengdu Medical College, Chengdu 610500, China

CorrespondingAuthor: YUAN Yuan Email: 14334202@qq.com

DOI: 10.3978/j.issn.2095-6959.2020.08.025

Foundation: This work was supported by the Special Scientific Research Project of Infectious Liver Disease (Shenzhen Jian’an) of Sichuan Medical Association, China (2017szja09).

Abstract

Objective: To study the efficacy of compound glycyrrhizin in the treatment of patients with hepatitis B cirrhosis and the effect on serum levels of IL-17, IL-6, TGF-β and MMP-2. Methods: Ninety patients with hepatitis B cirrhosis who were treated between January 2017 and December 2018 in Department of Infectious Diseases of the First Affiliated Hospital of Chengdu Medical College were divided into an observation group (n=45) and a control group (n=45). In the observation group, the compound glycyrrhizin was added on the basis of the treatment of the control group. The levels of the biochemical indicators, including alanine aminotransfem (ALT), glutamyltransferase (GGT), albumin (ALB), total bilirubin (TBIL); the liver fibrosis indicators, hyaluronic acid (HA), Laminin (LN), type IV collagen (IV-C) and type III procollagen (PC-III); and the cytokines, IL-17, IL-6, TGF-β, MMP-2 were detected. Results: After the treatment, the levels of ALT, GGT, and TBIL in the two groups were significantly reduced (P<0.05). After the treatment, the levels of ALT, GGT, and TBIL in the observation group were significantly lower than those in the control group (P<0.05). After treatment, the levels of LN, HA, IV-C and PC-III in the two groups of patients were significantly reduced (P<0.05). In the observation group, LN, HA, IV-C, and PC-III were significantly lower than the control group (P<0.05). After treatment, the serum levels of IL-17, IL-6, TGF-β, and MMP-2 in both groups were significantly reduced (P<0.05). The serum IL-17, IL-6, TGF-β, MMP-2 levels in the observation group were significantly lower than those in the control group (P<0.05). Conclusion: Compound glycyrrhizin can improve the liver function and reduce the levels of IL-17, IL-6, TGF-β and MMP-2 in patients with hepatitis B cirrhosis.
Keywords: compound glycyrrhizin; hepatitis B cirrhosis; IL-17; IL-6; TGF-β; MMP-2